| Estimation of the Warfarin dose with clinical and pharmacogenetic data JJA Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, Limdi NA ... N Engl J Med 360, 753-64, 2009 | 1880* | 2009 |
| Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes R Malik, G Chauhan, M Traylor, M Sargurupremraj, Y Okada, A Mishra, ... Nature genetics 50 (4), 524-537, 2018 | 1465 | 2018 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ... Clinical Pharmacology & Therapeutics 94 (3), 317-323, 2013 | 1068 | 2013 |
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 1006 | 2008 |
| A pharmacogenetic versus a clinical algorithm for warfarin dosing SE Kimmel, B French, SE Kasner, JA Johnson, JL Anderson, BF Gage, ... New England Journal of Medicine 369 (24), 2283-2293, 2013 | 886 | 2013 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ... Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011 | 784 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017 | 681 | 2017 |
| CYP4F2 genetic variant alters required warfarin dose MD Caldwell, T Awad, JA Johnson, BF Gage, M Falkowski, P Gardina, ... Blood, The Journal of the American Society of Hematology 111 (8), 4106-4112, 2008 | 667 | 2008 |
| PHARMACOGENOMICS: The Inherited Basis for Interindividual Differences in Drug Response WE Evans, JA Johnson Annual review of genomics and human genetics 2 (1), 9-39, 2001 | 600 | 2001 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott, K Sangkuhl, EE Gardner, CM Stein, JS Hulot, JA Johnson, ... Clinical Pharmacology & Therapeutics 90 (2), 328-332, 2011 | 598 | 2011 |
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ... Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008 | 540 | 2008 |
| β1‐Adrenergic Receptor Polymorphisms and Antihypertensive Response to Metoprolol JA Johnson, I Zineh, BJ Puckett, SP McGorray, HN Yarandi, DF Pauly Clinical Pharmacology & Therapeutics 74 (1), 44-52, 2003 | 421 | 2003 |
| Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ... Blood, The Journal of the American Society of Hematology 115 (18), 3827-3834, 2010 | 412 | 2010 |
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements CL Aquilante, TY Langaee, LM Lopez, HN Yarandi, JS Tromberg, ... Clinical Pharmacology & Therapeutics 79 (4), 291-302, 2006 | 383 | 2006 |
| Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics JJ Lima, DB Thomason, MHN Mohamed, LV Eberle, TH Self, JA Johnson Clinical Pharmacology & Therapeutics 65 (5), 519-525, 1999 | 346 | 1999 |
| Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci R Saxena, CC Elbers, Y Guo, I Peter, TR Gaunt, JL Mega, MB Lanktree, ... The American Journal of Human Genetics 90 (3), 410-425, 2012 | 330 | 2012 |
| Pharmacogenomics: challenges and opportunities DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ... Annals of internal medicine 145 (10), 749-757, 2006 | 317 | 2006 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update CR Lee, JA Luzum, K Sangkuhl, RS Gammal, MS Sabatine, CM Stein, ... Clinical pharmacology & therapeutics 112 (5), 959-967, 2022 | 316 | 2022 |
| Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ... The Lancet 382 (9894), 790-796, 2013 | 314 | 2013 |
| The pharmacogenetics research network: from SNP discovery to clinical drug response KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ... Clinical Pharmacology & Therapeutics 81 (3), 328-345, 2007 | 312 | 2007 |
Russ B AltmanProfessor Stanford UniversityΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα stanford.edu
